Alteramide B is a microtubule antagonist of inhibiting Candida albicans

• Published in: Biochimica et biophysica acta Vol. 1860; no. 10; pp. 2097 - 2106
• Main Authors: Ding, Yanjiao, Li, Yaoyao, Li, Zhenyu, Zhang, Juanli, Lu, Chunhua, Wang, Haoxin, Shen, Yuemao, Du, Liangcheng
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2016
• Subjects: Alteramide B; Animals; antagonists; Antifungal Agents - metabolism; Antifungal Agents - pharmacology; Apoptosis; Apoptosis - drug effects; binding sites; Binding Sites - drug effects; Candida albicans; Candida albicans - drug effects; Candida albicans - pathogenicity; Candida albicans SC5314; candidiasis; Candidiasis - drug therapy; Candidiasis - microbiology; cell cycle checkpoints; drugs; flow cytometry; fluorescence; gene overexpression; genes; Humans; Lactams, Macrocyclic - pharmacology; Lead - pharmacology; Lysobacter enzymogenes; mass spectrometry; mechanism of action; Membrane Potential, Mitochondrial - drug effects; Mice; microtubules; Microtubules - drug effects; molecular dynamics; Molecular Dynamics Simulation; molecular models; mutants; mutation; nuclear magnetic resonance spectroscopy; polymerization; Reactive oxygen species; Reactive Oxygen Species - metabolism; transmission electron microscopes; tubulin; Tubulin - metabolism; Tubulin Modulators - chemistry; Tubulin Modulators - pharmacology; yeasts; β-Tubulin; Candida albicans SC5314; Reactive oxygen species; Alteramide B; β-Tubulin; Apoptosis

Alteramide B (ATB), isolated from Lysobacter enzymogenes C3, was a new polycyclic tetramate macrolactam (PTM). ATB exhibited potent inhibitory activity against several yeasts, particularly Candida albicans SC5314, but its antifungal mechanism is unknown. The structure of ATB was established by exten...